Effects of a 6-month multi-strain probiotics supplementation in endotoxemic, inflammatory and cardiometabolic status of T2DM patients: a randomized, double-blind, placebo-controlled trial by Sabico, S et al.
1 
 
Effects of a 6-month Multi-Strain Probiotics Supplementation in 1 
Endotoxemic, Inflammatory and Cardiometabolic Status of T2DM Patients: 2 
A Randomized, Double-Blind, Placebo-Controlled Trial 3 
Shaun Sabico1, Ayah Al-Mashharawi2, Nasser M. Al-Daghri2, Kaiser Wani2, Osama E. Amer2, 4 
Danish S. Hussain2, Mohammed Ghouse Ahmed Ansari2, Mohammad S. Masoud2, Majed S. 5 
Alokail2, Philip G. McTernan3. 6 
1. Warwick Medical School, Division of Biomedical Sciences, University of Warwick, 7 
UHCW Trust, Clifford Bridge Road, Walsgrave, Coventry, CV2 2DX UK.  8 
2. Prince Mutaib Chair for Biomarkers of Osteoporosis, Biochemistry Department, College 9 
of Science, King Saud University, Riyadh 11451, Saudi Arabia  10 
3. School of Science and Technology, Department of Biosciences, Nottingham Trent 11 
University, Nottingham NG1 8NS, UK  12 
 13 
 14 
 15 
Corresponding author(s): 16 
Professor Philip G McTernan, BSc PhD 17 
 18 
School of Science and Technology, Department of Biosciences, Nottingham Trent University, 19 
Nottingham NG1 8NS, UK  20 
 21 
E: philip.mcTernan@ntu.ac.uk 22 
T: 0115 8483477 23 
 24 
Shaun Sabico MD, PhD 25 
 26 
Warwick Medical School, Division of Biomedical Sciences, University of Warwick, UHCW 27 
Trust, Clifford Bridge Road, Walsgrave, Coventry, CV2 2DX UK 28 
 29 
Prince Mutaib Bin Abdullah Chair on Osteoporosis 30 
Biochemistry Department 31 
College of Science, King Saud University 32 
PO Box, 2455, Riyadh, 11451 33 
Kingdom of Saudi Arabia 34 
Tel No: 0096614675939 35 
Fax No: 0096614675931 36 
E-mail: s.l.sabico@warwick.ac.uk 37 
 38 
2 
 
Summary 39 
Objective 40 
The aim of this trial was to characterize the beneficial effects of probiotics on decreasing endotoxin 41 
levels and other cardiometabolic parameters in Arab patients with type 2 diabetes mellitus 42 
(T2DM). 43 
Methods 44 
Saudi adults with naïve T2DM (n=61; 12 males and 18 females) were randomly allocated to 45 
receive twice daily placebo or 2.5×109cfu/gram of Ecologic®Barrier (multi-strain probiotics; 14 46 
males and 17 females) in a double-blind manner over a 6 month period, respectively. 47 
Anthropometrics were measured and fasting blood samples were collected to analyze endotoxin, 48 
glycemic parameters [glucose, insulin, c-peptide and homeostasis model assessment for insulin 49 
resistance (HOMA-IR)], lipids [triglycerides, total cholesterol, low and high-density lipoprotein 50 
(LDL and HDL, respectively) cholesterol and total/HDL-cholesterol ratio], inflammatory markers 51 
[tumor-necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) and C-reactive protein (CRP)] and 52 
adipocytokines [leptin, adiponectin and resistin] at baseline and after 3 and 6 months of 53 
intervention.  54 
Results 55 
Multi-strain probiotics supplementation for 6 months caused a significant decrease in circulating 56 
levels of endotoxin by almost 70% over 6 months, as well as glucose (38%), insulin (38%), 57 
HOMA-IR (64%), triglycerides (48%), total cholesterol (19%), total/HDL-cholesterol ratio (19%), 58 
TNF-α (67%), IL-6 (77%), CRP (53%), resistin (53%), and a significant increase in adiponectin 59 
(72%) as compared with baseline. Only HOMA-IR had a clinically significant reduction (-3.4, 60 
64.2%) in the probiotics group as compared to placebo group at all time points. No other clinically 61 
significant changes were observed between the probiotic or placebo group at 3 and 6 months in 62 
other markers.  63 
Conclusion 64 
Multi-strain probiotic supplementation over 6 months as a monotherapy significantly decreased 65 
HOMA-IR in T2DM patients, with the probiotic treatment group highlighting reduced 66 
inflammation and improved cardiometabolic profile. As such, multi-strain probiotics is a 67 
promising adjuvant anti-diabetes therapy.  68 
Trial Registration: ClinicalTrials.gov Identifier: NCT01765517 69 
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1. Introduction 71 
In recent years there has been intense commercial interest in understanding the role of 72 
human microbiome in diseases and factors that can relieve it, with the use of pre-biotic and pro-73 
biotic often in inflammatory intestinal disorders making it an emerging biomedical industry 74 
projected to be worth $46.56 billion by 2020 [1]. Despite this interest there has been conflicting 75 
evidence into the effectiveness of probiotics in health and disease per se with limited insight into 76 
the use of prebiotics and probiotics for the management type 2 diabetes mellitus (T2DM) [2-5]; 77 
despite the knowledge that T2DM is also considered an inflammatory chronic condition. Prior 78 
studies in T2DM subjects has shown the importance of the gut derived gram negative bacterial 79 
fragment lipopolysaccharide (LPS, endotoxin) which can overgrow in the intestine, induce a leaky 80 
gut, and allow endotoxin to enter into the circulation and induce systemic inflammation [6]. Prior 81 
studies have also shown that the use of diet and/or surgery for weight reduction can lower 82 
endotoxin-induced inflammation [7-9], which, suggests that manipulation of the gut microbiota 83 
with an appropriate pro-biotic may also have significant health effects [10]. Since the gut 84 
microbiome is the main reservoir of endotoxin, probiotics supplementation may alter its levels by 85 
modifying its composition and strengthening the gut epithelial barrier [11, 12].   86 
Few studies to date have examined the effects of probiotics on systemic levels of endotoxin 87 
in chronic, non-communicable diseases. Those that have examined the specific impact of 88 
probiotics on endotoxin and associated metabolic diseases have shown conflicting outcomes. 89 
Probiotics use in cirrhotic patients has shown a positive 25% reduction in systemic endotoxin [13], 90 
while a more recent review indicated the effects on circulating endotoxin was minimal [14]. 91 
Although in animal studies, where diet is more easily controlled, more consistent evidence 92 
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suggests that probiotics supplementation may be beneficial in the use of insulin-resistant diseases 93 
[15]. The few human intervention trials that have been conducted appear to support the animal 94 
studies with a recent meta-analysis of 12 studies implicating that probiotics give rise to significant 95 
improvements in HbA1c and fasting insulin amongst subjects with T2DM [16]. Nevertheless, the 96 
majority of the interventional studies conducted to date with probiotics use in subjects with T2DM 97 
have tended to be either short-term studies, no longer than 3 months and/or mono-strains were 98 
used as supplementation [17, 18]. To the best of our knowledge, there is limited evidence on the 99 
effects of a long duration, multi-strain probiotics supplementation on systemic endotoxin levels 100 
amongst T2DM subjects. This study therefore sought to test the hypothesis that multi-strain 101 
probiotics supplementation reduces endotoxin levels and consequently improve cardiometabolic 102 
profile in an Arab T2DM population where metabolic risk is high. 103 
2. Methods 104 
2.1 Participants and study design 105 
The study was a 6-month, single-center, double-blind, randomized, placebo-controlled 106 
clinical trial. The trial protocol has been previously published and was also registered at the US 107 
National Institute of Health (NIH) (ClinicalTrials.gov Identifier: NCT01765517) [19]. Ethical 108 
approval was obtained from the Ethics Committee in the College of Science, King Saud University 109 
in Riyadh, Saudi Arabia.  110 
For this study 150 adult Saudi participants [73 females (46 (63%) menopause), 77 males, 111 
aged 30-60 years old) with newly diagnosed T2DM (<6 months) were initially recruited by the 112 
research team for intervention from January 2014 to February 2016. All participants were patients 113 
visiting the outpatient department of King Salman Hospital, Riyadh, Saudi Arabia. Patients with 114 
diabetes complications (retinopathy, neuropathy, nephropathy, etc.) and poor glycemic control 115 
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(HbA1c > 7%) as noted in their medical records were excluded. Participants on prebiotics, 116 
probiotics, or antibiotics treatment 6 weeks before inclusion, lactating or pregnant women, on 117 
insulin or its analogues and those with gastrointestinal diseases were excluded. Sample size 118 
calculation was previously done based on the primary outcome (endotoxin), considering 80% 119 
power at α=0.05 [19].  120 
Circulating endotoxin level was measured as a primary outcome, whilst anthropometrics, 121 
glycemic parameters, lipid profile, inflammatory and adipocytokine markers were measured as 122 
secondary outcomes. Significant differences in the assessment between placebo and probiotics 123 
group after random allocation served as baseline covariate variables in this study. 124 
2.2 Randomization and Blinding 125 
All participants were allocated (1:1) to receive either probiotics or placebo. The 126 
randomization scheme was computer generated by Winclove using permuted blocks with block 127 
size equal to 4. True allocation concealment was done since the research personnel involved cannot 128 
adjust randomization or discern the actual treatment the patient is given.  129 
2.3 Study Protocol 130 
The probiotics group was allocated with sachets [2g freeze-dried powder of the probiotic 131 
mixture Ecologic®Barrier (Winclove probiotics, the Netherlands) (2.5×109cfu/gram)] which 132 
contains the following strains: Bifidobacterium bifidum W23, Bifidobacterium 133 
lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus 134 
casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19 and Lactococcus lactis W58. 135 
This probiotic combination has been previously investigated for its ability to improve endothelial 136 
barrier and its potency to inhibit mast cell activation, inhibit pro-inflammatory cytokines decrease 137 
endotoxin load [20]. The placebo group was allocated the same sachets without the probiotic 138 
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strains (2 grams freeze-dried maize starch and maltodextrins). All participants were asked to 139 
consume their assigned treatment twice daily (dissolving contents in glass of water) before 140 
breakfast and before bed time. Anthropometrics were measured and included height (cm), weight 141 
(kg), blood pressure (mmHg) waist and hip measurements (cm), body mass index (BMI kg/m2) 142 
and waist-hip ratio (WHR) at baseline, 3 months and after 6 months of treatment. Fasting blood 143 
samples were also collected during those time points. All blood samples were centrifuged, serum 144 
samples separated, put on ice and immediately delivered to Prince Mutaib Chair for Biomarkers 145 
of Osteoporosis (PMCO) in King Saud University (KSU) for storage at -20'C until further analysis. 146 
To monitor compliance, subjects were asked to return once a month to be asked for side effects 147 
and to return unused sachets for fresh refill.  148 
2.4 Biochemical Analyses 149 
Fasting serum samples were analyzed for glucose and lipid profile [total cholesterol, high 150 
density lipoprotein (HDL) cholesterol and triglycerides] using Konelab routine analyzer (Konelab, 151 
Espoo, Finland). LDL-cholesterol was calculated using the Friedewald equation [21]. Serum tumor 152 
necrosis factor (TNF)α, interleukin (IL)-6, leptin, adiponectin and resistin were measured using 153 
the Milliplex Map (Millipore, Billerica, MA, USA) in the FlexMAP 3D (Luminex Corp, Austin, 154 
TX, USA) . Minimum detectable concentrations (MDC) were as follows: TNFα, 0.14pg/ml; IL-6, 155 
0.4pg/ml; leptin, 85.4pg/ml; adiponectin, 145.4pg/ml and resistin, 6.7pg/ml. The intra-assay 156 
variation was 1.4-7.9% and inter-assay variation of <21%. Serum insulin and C-peptide were 157 
measured using electrochemiluminescence assay (Roche Diagnostics, Germany). C-reactive 158 
protein (CRP) [intra-assay precision (4.4-8.3) and inter-assay precision (6.0-7.0)] (R&D Systems, 159 
MN, USA). Homeostasis model assessment (HOMA IR) was calculated as the product of insulin 160 
(uU/ml) and glucose (mmol/l) divided by 22.5 [22]. Endotoxin (primary endpoint) was measured 161 
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using a limulus amebocyte lysate (LAL) quantitative kinetic assay (Lonza, MD, USA). As serum 162 
is very inhibitory to this assay a spike recovery was performed using a sample dilution of 1:40. 163 
The recovery spike was 60% and was within the acceptable range of 50-200%. All serum samples 164 
were analyzed at baseline, 3 months and after 6 months of treatment. 165 
2.5 Data Analyses 166 
Data were analyzed using SPSS (version 16.5 Chicago, IL, USA). Statistical analysis was 167 
performed using Intention-to-treat (ITT) analysis, where missing data were dealt by using the last 168 
observation carried forward (LOCF) method. Per-protocol analyses was done only for primary 169 
endpoint (endotoxin). All normally distributed data were presented as mean and standard 170 
deviations, while non-normally distributed data was presented as median and interquartile range. 171 
Furthermore, categorical data was presented as frequencies and percentages (%). Independent 172 
sample Student T-test and Mann Whitney U test was used to determine significant differences 173 
between groups at baseline. Mixed method analysis of covariance (ANCOVA) was used to 174 
determine within and between group differences after adjusting for baseline covariates including 175 
WHR, leptin, TNF-α, IL-6, endotoxin, glucose and total cholesterol/HDL ratio. A further sub-176 
analysis was done to determine the effect of sex in the intervention and repeated measures 177 
ANCOVA revealed no significant effect.  All non-normal variables including glucose (mmol/l), 178 
insulin (IU/ml), c-peptide (ng/ml), HOMA-IR, TNF alpha (pg/ml), IL-6 (pg/ml), CRP (ug/ml), 179 
leptin (pg/ml), adiponectin (ug/ml), resistin (ng/ml) and endotoxin (IU/ml) (variables that did not 180 
follow a normal distribution curve) were transformed prior to parametric testing. Intervention 181 
effects were presented at 95% confidence interval (CI). A p-value <0.05 was considered 182 
statistically significant. 183 
 184 
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3. Results 185 
Of the 150 participants that were recruited, 96 were randomized, 78 completed 3 months and 186 
61 completed the entire trial (probiotics group, n=31; placebo group, n=30). The flowchart of the 187 
trial is presented in figure 1. Baseline comparison showed no significant differences in both groups 188 
except WHR, glucose, total cholesterol, total/HDL-cholesterol, TNF-α, IL-6, leptin and endotoxin 189 
(Table 1). The most common reasons for drop out included loss to follow-up and poor compliance. 190 
Flatulence was the most common complaint (N=5, 1 in the placebo group and 4 in the probiotics 191 
group) during the first weeks of trial in both placebo and probiotics group (not included in tables). 192 
3.1 Changes in Anthropometrics and Clinical Measures  193 
At baseline, the placebo group had a significantly higher WHR and a significantly lower 194 
mean arterial pressure than the probiotics group. Between-group comparisons showed no 195 
significant changes in all anthropometric and clinical measures post intervention (Table 2).  196 
3.2 Changes in Glycemic Indices  197 
Fasting glucose levels were significantly higher in the probiotics than the placebo group at 198 
baseline [11.7mmol/l (8.4-16.4) versus 7.1mmol/l (5.7-11.2)]. After adjusting for baseline 199 
covariates, between group-comparisons showed no significant difference in glucose levels 200 
between placebo and probiotics groups at 3 months [1.0mmol/l (14.3%) vs -3.2mmol/l (-27.4%)] 201 
and after 6 months [1.1mmol/l (15.7%) vs -4.5mmol/l (-38.5%)]. No difference was also observed 202 
in C-peptide levels [0.80ng/ml (800%) vs -0.30ng/ml (-75%)] at 6 months. A borderline significant 203 
difference was observed in insulin levels [-0.30IU/ml (-2.4%) vs –3.80IU/ml (-38.4%)] at 6-month 204 
comparison and clinically significant differences were noted in HOMA-IR at 3 months [0.0 (0%) 205 
vs -3.2 (-60.4%)] and after 6 months [0.80 (20.5%) vs -3.40 (-64.2%)] in favor of the probiotics 206 
group. Within group comparisons showed that in the placebo group, there was a significant 207 
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increase in C-peptide levels at 6 months as compared to both baseline and 3 months. The rest of 208 
the glycemic parameters in the placebo group did not significantly change over time. In the 209 
probiotics group, a significant decrease was observed in glucose, insulin and HOMA-IR values 210 
overtime. Median levels of C-peptide significantly decreased only after 6 months. (Table 3).  211 
3.3 Changes in Lipid Profile  212 
LDL- and total cholesterol as well as total/HDL-cholesterol ratio were significantly higher 213 
in the probiotics group than placebo at baseline. Between group comparisons showed no 214 
differences in placebo and probiotics groups over-all in levels of triglycerides [-0.10mmol/l (-215 
4.6%) vs -1.20mmol/l (-48%)], total cholesterol [-0.30mmol/l (-5.8%) vs -1.10mmol/l (-19%)], 216 
HDL-cholesterol [-0.10mmol/l (-9.1%) vs -0.30mmol/l (30%)], LDL-cholesterol [-0.10mmol/l 217 
(9.7%) vs – 0.80mmol/l (-22.2%)] and total/HDL-cholesterol ratio [-0.30 (-5.8%) vs -1.10 (-19%)]. 218 
Within group analysis showed no changes in the placebo group over time. In the probiotics group, 219 
significant improvements were observed in terms of decreased triglycerides, total cholesterol and 220 
total/HDL cholesterol ratio (Table 4).  221 
3.4 Changes in Inflammatory Markers  222 
At baseline, the probiotics group had a significantly higher median levels of TNFα and IL6 223 
than placebo group. Between-group comparisons post-intervention showed no significant 224 
differences in placebo and probiotic groups in levels of TNFα [-0.20pg/ml (-40%) vs -0.60pg/ml 225 
(-66.7%)], IL-6 [-2.8pg/ml (-77.8%) vs -3.9pg/ml (-76.5%)] and C-reactive protein [0.40ug/ml 226 
(13.3%) vs -2.9ug/ml (-52.7%)]. Within group comparisons however showed that all inflammatory 227 
markers significantly improved over time in the probiotics group and these changes were not 228 
observed in the placebo group (Table 5). 229 
3.5 Changes in Endotoxin levels and Adipocytokine Profile  230 
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Endotoxin was significantly higher in the probiotics group than placebo at baseline. 231 
Furthermore, no differences in baseline adipocytokines were observed except for levels of leptin 232 
being significantly higher in the probiotics than the placebo group. Between group comparisons 233 
after 6 months showed no differences in both groups in levels of endotoxin [0.80IU/ml (38.1%) 234 
vs. -3.20IU/ml (-69.6%)], leptin [-1.1pg/ml (-28.2%) vs. -2.7pg/ml (-46.6%)], adiponectin 235 
[0.0µg/ml (0%) vs. 6.1µg/ml (71.8%)], and resistin [5.0ng/ml (79.4%) vs. -6.8ng/ml (-58.1%)]. 236 
Within group comparisons showed a significant increase in resistin levels after 6 months compared 237 
to baseline (p<0.05) as well as a significant increase in endotoxin levels after 6 months as 238 
compared to 3 months in the placebo group. In the probiotics group post-intervention, there was a 239 
significant improvement in endotoxin (Figure 2) and adiponectin levels, and a significant decrease 240 
in resistin. No significant changes in either group were noted in leptin levels (Table 6).  241 
4. Discussion 242 
The ambition of this randomized controlled study was to determine primarily the systemic 243 
endotoxin-lowering capability of a multi-strain probiotic supplementation and whether such 244 
treatment would result in improved cardiometabolic profile in patients with T2DM. From this 245 
study, it was observed that circulating endotoxin levels were significantly reduced post-246 
intervention in the probiotics group, whilst the placebo group remained unchanged by time. In 247 
addition, comparison between groups also showed a clinically significant difference in HOMA-IR 248 
with improvement in insulin sensitivity in the probiotic group. The noted associated improvement 249 
in endotoxin levels and HOMA-IR has been observed in other diet or medicinal intervention 250 
studies using T2DM subjects [7, 8]. In conjunction with reduction in endotoxin levels in the 251 
probiotic group at six months there were also associated improvements in cholesterol, Total 252 
cholesterol/HDL ratio, and glycemic control from baseline in group analysis supporting the 253 
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concept that probiotics can provide cardiometabolic protective effects. Noting that the placebo 254 
group did not appear comparable to the probiotic group from baseline biochemical data gathered.  255 
Previous studies have tried to evaluate the beneficial effects of probiotics in T2DM with the 256 
ultimate cardiometabolic benefits requiring more than 3 months, with our study suggesting 6 257 
month follow up may highlight promising findings [23-27]. Our study is, to our knowledge, the 258 
first to demonstrate the effects of a multi-strain probiotic supplement given over 6-months in the 259 
Arab T2DM population, using endotoxin as the primary endpoint. It is also important to stress that 260 
the probiotic supplementation in this present study was used as a standalone treatment given in the 261 
absence of exercise and diet-related modifications in the intervention or lifestyle control in a 262 
culture with easy access to excess food. While this is not the first interventional study undertaken 263 
on the effects of probiotics in patients with T2DM, our protocol addressed previous trials concerns 264 
for a longer duration and use of multiple strains, which highlighted cardiometabolic benefits in the 265 
probiotic group from baseline to six months. Clearly the 6 month time point was important to 266 
observe changes as the most significant changes were noted which affirms a recent meta-analysis 267 
of Hu and colleagues observed, where trials with longer durations of intervention using multiple 268 
probiotic strains had more beneficial cardiometabolic effects in patients with T2DM [28].  269 
This present study showed significant improvements in the endotoxin levels of the probiotic 270 
group overtime, although not clinically significant as compared to placebo group at 6 months. 271 
However, the T2DM patients in the probiotic group began the study at a significantly higher 272 
baseline endotoxin level, despite noted comparability for BMI, age and gender. Furthermore, 273 
biochemically the probiotic intervention group began the study with significantly raised glucose 274 
levels, diastolic blood pressure and inflammatory status as well. This therefore would have affected 275 
the 6-month comparison as the baseline groups were not comparable which may have been a 276 
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challenge with using newly diagnosed T2DM patients; despite best efforts to limit confounders in 277 
the study. Such discrepancies between the two groups could also have been due be due to sample 278 
size difference, duration of intervention and patient selection [29]. However, there was a noted  279 
70% drop in endotoxin level in those subjects on the probiotic over six months compared with a 280 
net effect of zero change in the control placebo group over the same period. 281 
The reduction in systemic endotoxin level in probiotic group may have arisen as probiotics are 282 
known to alter the gut microbiome, act as competitive inhibition with other bacterial components 283 
via adherence to the mucosa and epithelium, strengthen the intestinal epithelial barrier function 284 
translating to reduced circulating endotoxin, and modification of the immune response in favor of 285 
the host [30, 31]. The use of 8 strains in our study most likely provided a cumulative effect on 286 
changes to the gut, strengthen by the longer duration of intervention.  287 
The effects of the probiotic supplementation on weight loss was not observed. Other studies 288 
have noted changes in weight but these have tended to be when the probiotic is taken as part of a 289 
either a hypocaloric diet and/or use of bioactive compounds, factors that were not included in our 290 
study [32]. Furthermore, no substantial effect was observed in blood pressure despite the longer 291 
duration of treatment in this study. Prior studies have noted changed in animal studies but these 292 
again have tended to be when taken with other agents such as prebiotics and symbiotics [33] or in 293 
human studies when part of a prescribed dietary regimen [34].  294 
It was also observed in this present study the use of the probiotics led to improvement in 295 
adipocytokines with a reduction in TNF, IL-6, CRP, resistin and a rise in adiponectin at six 296 
months, which was not observed in the placebo group, even though interaction effects at set 297 
intervals noted no significant difference. This lack of effect between groups largely appeared to 298 
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arise due to the raised baseline endotoxin and adipokine levels in the probiotic group compared 299 
with the placebo group.  300 
Previous observations have suggested that endotoxins from non-commensal bacteria may 301 
affect adipocytokine levels secondary to translocation induction of several intestinal microbial 302 
antigens into the circulation, creating an altered adipokine profile and intestinal dysbiosis [35]. 303 
Certain probiotics, specifically lactic acid bacteria strains, have demonstrated in vitro that they can 304 
differentially modulate adipokine expression and the inflammatory response [36]. It is noteworthy 305 
that 6 of the 8 probiotic strains used in this study belong to the lactic acid bacteria class. However, 306 
how probiotics directly or indirectly influence adipocytokine levels requires further evaluation, as 307 
the effects may be secondary to improved insulin sensitivity and stronger intestinal barrier 308 
function. 309 
The authors acknowledge several limitations. Successful colonization of probiotics in the 310 
intestinal tract were not obtained, although absence of gut microbiome data does not necessarily 311 
mean absence of efficacy [37]. The study also had a low response rate, partly because majority of 312 
the patients who initially showed interest to participate declined to continue after a few days, 313 
probably because the concept of ingesting live bacteria to improve metabolic status is relatively 314 
unheard of in this part of the world. The actual sample size was below the proposed sample size, 315 
therefore, the actual power was compromised producing impacting the final clinical findings. The 316 
use of prebiotics instead of probiotics might prove to be more beneficial in the region, given the 317 
reluctance to use probiotics. Another limitation is the persistent discrepancy between baseline 318 
values of the probiotics and the placebo group despite randomization, as is the nature of clinical 319 
trials. Baseline characteristics show that while BMI, age and gender were matched for both placebo 320 
and probiotics group, the probiotics group were actually cardiometabolically less metabolically 321 
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healthy than the placebo group. While this was addressed by adjusting analyses for baseline 322 
differences, the additional adjustments of covariates made it more difficult to elicit the desired 323 
treatment effect because of the added statistical stringency due to the small cohort. Finally, analysis 324 
was not controlled for diet or exercise, which were not assessed, factors that may considerably 325 
affect the gut microbiota. 326 
Despite the limitations and the rigorous analyses undertaken, a significant improvement 327 
was observed in terms of decreased HOMA-IR over time. As HOMA-IR is intricately linked to 328 
most of the cardiometabolic indices measured, the clinically significant improvement suggests that 329 
probiotics supplementation do confer beneficial effects when consumed by the T2DM population. 330 
The present clinical trial is the first in the Arab T2DM population; hence, the present findings may 331 
prove clinically beneficial for this region. The present study is also one of the longest randomized 332 
controlled trials to demonstrate the beneficial effects of a multi-strain probiotic supplementation 333 
in improving the HOMA-IR of T2DM patients. Clinical trials on probiotic supplementation in the 334 
Arabic T2DM population has never been performed previously. This is important since the gut 335 
microbiome is highly affected not only by the health status of the individual, but more so by 336 
geography and ethnicity [38]. Findings of the present study therefore add value to the current 337 
literature in terms of ethnic-specific effects of probiotics supplementation among patients with 338 
T2DM. 339 
In summary, a daily multi-strain probiotic supplementation for 6 months can significantly 340 
improve HOMA-IR, reduce endotoxin and inflammatory adipokine levels amongst Arab T2DM 341 
subjects. The significant improvement in insulin resistance in favor of the probiotics group despite 342 
the low sample size and the rigorous analysis performed merit clinical attention. Findings from the 343 
study offer important information that will expand our current understanding on how multi-strain 344 
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probiotic supplements work in the diabetic population arising from a relatively homogenous and 345 
understudied ethnic population. The findings also shed light on the challenges of conducting 346 
randomized clinical trials in this area of the world where such studies that offer high level of 347 
evidence are still evolving and would require greater input and participation from the general 348 
population. This study nonetheless recommends the use of multiple-strain probiotics as a 349 
supplemental therapy in subjects with T2DM. 350 
 351 
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Figure 1. CONSORT Flow Chart detailing participants’ recruitment, randomization and allocation. 508 
Figure 2. Changes in endotoxin levels in probiotics and placebo group using A) Intent-to-Treat (ITT) and 509 
B) Per-Protocol Analyses 510 
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Table 1. Baseline Characteristics according to Intervention Groups.  517 
 Parameters Placebo  Probiotics  P-value 
N 39 39  
M/F 21/18 19/20  
Age (Years) 46.6 ± 5.9 48.0 ± 8.3 0.40 
BMI (kg/m2) 30.1 ± 5.0 29.4 ± 5.2 0.56 
Waist-Hip Ratio 1.0 ± 0.1 0.9 ± 0.1 0.02 
Systolic BP (mmHg) 129.5 ± 10.3 133.4 ± 14.0 0.17 
Diastolic BP (mmHg) 78.6 ± 8.6 83.2 ± 12.0 0.06 
Mean Arterial Pressure (MAP) 95.5 ± 7.7 100.0 ± 10.9 0.05 
Glycemic Profile 
Glucose (mmol/l) 7.1 (5.7 - 11.2) 11.7 (8.4 - 16.4) 0.001 
Insulin (IU/ml) 13.0 (7.5 - 18.7) 9.9 (7.7 - 16.4) 0.62 
C-peptide (ng/ml) 0.1 (0.1 - 0.4) 0.5 (0.0 - 1.9) 0.07 
HOMA-IR 4.1 (2.3-7.5) 5.3 (3.5-10.2) 0.99 
Lipid Profile 
Triglycerides (mmol/l) 2.2 ± 1.4 2.5 ± 1.4 0.36 
Total Cholesterol (mmol/l) 5.2 ± 1.0 5.8 ± 1.3 0.04 
HDL-Cholesterol (mmol/l) 1.1 ± 0.3 1.0 ± 0.3 0.09 
LDL-cholesterol (mmol/l) 3.2 ± 0.9 3.7 ± 1.2 0.02 
Total Cholesterol/HDL-Chol Ratio 5.0 ± 1.3 6.5 ± 2.2 0.001 
Inflammatory Markers Profile  
TNF alpha (pg/ml) 0.5 (0.2-0.9) 0.9 (0.3-1.3) 0.01 
IL-6 (pg/ml) 3.7 (1.9-11.4) 5.6 (3.0-19.1) 0.04 
CRP (ug/ml) 2.7 (1.9-6.2) 5.6 (2.8-6.4) 0.29 
Adipocytokine Profile 
Leptin (pg/ml) 3.6 (1.4-7.6) 5.8 (2.5-17.2) 0.04 
Adiponectin (ug/ml) 11.4 (8.7-16.4) 8.3 (6.5-18.0) 0.09 
Resistin (ng/ml) 6.3 (4.2-11.4) 10.8 (5.3-16.9) 0.12 
Endotoxin (IU/ml) 2.2 (1.2-4.5) 4.8 (2.6-8.4) 0.002 
Note: Data presented as Mean ± SD for normally distributed data while non-normally normally distributed data are 518 
presented as Median (inter-quartile range). P-value significant at p<0.05.  519 
 520 
 521 
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Table 2. Anthropometric Measures Before and After Intervention with Placebo or Probiotics in T2DM Patients.  
Parameter Placebo (N=30) Probiotics (N=31) Intervention Effects (CI 95%) 
Baseline 3 months 6 months Baseline 3 months 6 months 0-3 months 0-6 months Over-all 
BMI (kg/m2) 30.1 ± 5.0 30.2 ± 5.0 29.7 ± 5.0 29.4 ± 5.2 29.3 ± 5.3 29.4 ± 5.2 
-2.10  
(-6.4-2.1) 
-1.88  
(-6.1-2.3) 
-1.96  
(-6.2-2.2) 
Change (%) at 3m  0.1 (0.3) -0.10 (-0.3) 
Change (%) at 6m  -0.4 (-1.3) 0.0 (0.0) 
WHR 1.0 ±0.1 1.0 ±0.1 1.0 ±0.1 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 
-0.09  
(-0.1- -0.03) 
-0.08  
(-0.1- -0.02) 
-0.08  
(-0.1- -0.03) 
Change (%) at 3m  0.0 (0.0) 0.0 (0.0) 
Change (%) at 6m  0.0 (0.0) 0.0 (0.0) 
SBP (mmHg) 129.5 ± 10.3 129.9 ± 11.1 129.2 ± 11.3 134.8 ± 14.6 129.0 ± 11.4          130.6 ± 12.5 
-2.33  
(-10.9-6.2) 
-1.13  
(-9.8-7.6) 
-1.98  
(-10.4-6.5) 
Change (%) at 3m  0.4 (0.3) -5.8 (-4.3) 
Change (%) at 6m  -0.3 (-0.2) -4.2 (-3.1) 
DBP (mmHg) 78.6 ± 8.6 79.8 ± 8.1 77.3 ± 9.1 83.6 ± 11.8 79.8 ± 11.5 81.0 ±11.7 
0.45  
(-7.0-7.9) 
2.07  
(-6.2-10.3) 
0.81  
(-6.7-8.4) 
Change (%) at 3m  1.2 (1.5) -3.8 (-4.6) 
Change (%) at 6m  -1.3 (-1.6) -2.6 (-3.1) 
MAP (mmHg) 95.7 ± 7.7 96.5 ± 7.8 100.7 ± 11.1 100.6 ± 11.1 96.2 ± 9.7 97.5 ± 9.9 
-0.48  
(-7.2-6.2) 
1.00  
(-6.2-8.2) 
-0.12  
(-6.8-6.6) 
Change (%) at 3m  1.0 (1.0) -4.4 (-4.4) 
Change (%) at 6m  5.2 (5.4) -3.1 (-3.1) 
Note: Data was presented as mean ± SD. Results were obtained from mixed method ANCOVA adjusted for baseline covariates; SBP, systolic blood pressure; 
DBP, diastolic blood pressure; MAP, mean arterial pressure; 3m, 3 months; 6m, 6 months. 
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Table 3. Glycaemic Parameters Before and After Intervention with Placebo or Probiotics in T2DM Patients.  
Parameter Placebo (N=30) Probiotics (N=31) Intervention Effects (CI 95%) 
Baseline 3 months 6 months Baseline 3 months 6 months 0-3 months 0-6 months Over-all 
Glucose (mmol/l) 
7.0  
(5.7-11.2) 
8.0  
(5.9-11.4) 
8.1  
(6.9-11.4) 
11.7  
(8.4-16.4) 
8.5a  
(6.2-10.9) 
7.2ab  
(5.3-9.1) 0.10  
(-0.01-0.2) 
0.07  
(-0.04- 0.2) 
0.03  
(-0.07-0.1) Change (%) at 3m  1.0 (14.3) -3.2 (-27.4) 
Change (%) at 6m  1.1 (15.7) -4.5 (-38.5) 
Insulin (IU/ml) 
12.4  
(8.0-18.7) 
10.8  
(8.3-15.5) 
12.1 
(8.0-17.4) 
9.9  
(7.7-16.4) 
6.9a 
(4.5-9.8) 
6.1a 
(3.6-9.6) -0.12  
(-0.3-0.1) 
-0.19  
(-0.4-0.03) 
-0.20  
(-0.4-0.01) Change (%) at 3m  -1.6 (-12.9) -3.0 (-30.3) 
Change (%) at 6m  -0.3 (-2.4) -3.8 (-38.4) 
C-peptide (ng/ml) 
0.1 
(0.1-0.5) 
0.2 
(0.1-0.9) 
0.9a 
0.1-1.9) 
0.4 
(0.0-1.8) 
0.1a 
(0.0-0.3) 
0.1 
(0.0-0.4) 0.44  
(-0.02-0.9) 
0.24  
(-0.2-0.6) 
0.20  
(-0.2-0.6) Change (%) at 3m  0.1 (100.0) -0.3 (-75.0) 
Change (%) at 6m  0.8 (800.0) -0.3 (-75.0) 
HOMA-IR 
3.9 
(2.3-6.5) 
3.9 
(3.3-6.0) 
4.7 
(3.6-6.7) 
5.3 
(3.5-10.2) 
2.1a 
(1.5-5.2) 
1.9a 
(1.2-3.1) -0.21* 
(-0.4- -0.02) 
-0.34** 
(-0.6- -0.12) 
-0.38** 
(-0.6- -0.17) Change (%) at 3m  0.0 (0.00) -3.2 (-60.4) 
Change (%) at 6m  0.80 (20.5) -3.4 (-64.2) 
Note: Data was presented as median (interquartile range). Results were obtained from mixed method ANCOVA adjusted for baseline covariates; superscript “a” 
denotes significance compared to baseline; superscript “b”  denotes significance compared to 3 months; * denotes significance at p<0.05; ** denotes significance 
at p<0.01; 3m, 3 months; 6m, 6 months. Significant at p<0.05. 
 
 
 
 
 
 
 
24 
 
Table 4. Lipid Profile Before and After Intervention with Placebo or Probiotics among T2DM Patients.  
Parameter Placebo (N=30) Probiotics (N=31) Intervention Effects (CI 95%) 
Baseline 3 months 6 months Baseline 3 months 6 months 0-3 months 0-6 months Over-all 
TG (mmol/l) 2.2 ± 1.4 2.0 ± 0.8 2.1 ± 1.6 2.5 ± 1.4 1.7 ± 0.7a 1.3 ± 0.6a 
-0.04  
(-0.7-0.6) 
-0.65  
(-1.5-0.2) 
-0.51  
(-1.2-0.2) 
Change (%) at 3m  -0.2 (-9.1) -0.8 (-32.0) 
Change (%) at 6m  -0.1 (-4.6) -1.2 (-48.0) 
T.Chol (mmol/l) 5.2 ± 1.0 4.7 ± 0.9 4.9 ± 1.0 5.8 ± 1.3 5.1 ± 0.9 4.7 ± 1.1a 
-0.35  
(-1.1-0.4) 
-0.63  
(-1.4-0.1) 
-0.47  
(-1.2-0.2) 
Change (%) at 3m  -0.5 (-9.6) -0.7 (-12.1) 
Change (%) at 6m  -0.3 (-5.8) -1.1 (-19.0) 
HDL-C (mmol/l) 1.1 ± 0.3 1.0 ± 0.3 1.0 ± 0.4 1.0 ± 0.3 1.1 ± 0.3 1.3 ± 0.4 
-0.05  
(-0.2-0.1) 
-0.06  
(-0.2-0.1) 
-0.04  
(-0.2-0.1) 
Change (%) at 3m  -0.1 (-9.1) 0.1 (10.0) 
Change (%) at 6m  -0.1 (-9.1) 0.3 (30.0) 
LDL-C (mmol/l) 3.1 ± 0.9 2.8 ± 0.9a 2.8 ± 1.0 3.6 ± 1.3 3.2 ± 0.9 2.7 ± 1.0 
-0.30  
(-0.9-0.3) 
-0.28  
(-0.9-0.4) 
-0.22  
(-0.8-0.4) 
Change (%) at 3m  -0.3 (-9.7) -0.4 (-11.1) 
Change (%) at 6m  -0.1 (-9.7) -0.8 (-22.2) 
T.Chol/HDL ratio 5.2 ± 1.0 4.7 ± 0.9 4.9 ± 1.0 5.8 ± 1.3 5.1 ± 0.9 4.7 ± 1.1a 
1.12  
(-0.6-2.9) 
0.19  
(-0.7-1.1) 
0.49  
(-0.8-1.8) 
Change (%) at 3m  -0.5 (-9.6) -0.7 (-12.1) 
Change (%) at 6m  -0.3 (-5.8) -1.1 (-19.0) 
Note: Data was presented as mean ± SD. Results were obtained from mixed method ANCOVA adjusted for baseline covariates; superscript “a” denotes significance 
compared to baseline; TG, triglycerides, T.Chol, total cholesterol; 3m, 3 months; 6m, 6 months. Significant at p<0.05. 
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Table 5. Inflammatory Markers Before and After Intervention with Placebo or Probiotics among T2DM Patients.  
Parameter Placebo (N=30) Probiotics (N=31) Intervention Effects (CI 95%) 
Baseline 3 months 6 months Baseline 3 months 6 months 0-3 months 0-6 months Over-all 
TNF-α (pg/ml) 
0.5  
(0.2-0.8) 
0.5 
(0.2-0.8) 
0.3 
(0.2-0.8) 
0.9 
(0.4-1.2) 
0.6 
(0.3-0.9) 
0.3ab 
0.2-0.7) 0.16  
(-0.03- 0.3) 
0.07  
(-0.1-0.3) 
0.05  
(-0.1-0.2) Change (%) at 3m  0 (0) -0.3 (-33.3) 
Change (%) at 6m  -0.2 (-40.0) -0.6 (-66.7) 
IL-6 (pg/ml) 
3.6 
(1.4-11.4) 
0.8 
0.6-4.4) 
0.8 
0.7-3.8) 
5.1 
(2.7-18.8) 
1.4a 
(0.7-18.0) 
1.2a 
(0.8-3.6) -0.20  
(-0.6-0.2) 
-0.14  
(-0.5-0.2) 
-0.21  
(-0.6-0.2) Change (%) at 3m  -2.8 (-77.8) -3.7 (-72.6) 
Change (%) at 6m  -2.8 (-77.8) -3.9 (-76.5) 
CRP (µg/ml) 
3.0 
(1.9-6.2) 
2.9 
(1.5-4.7) 
3.4 
(2.6-5.6) 
5.5 
(2.7-6.1) 
3.1a 
(1.4-5.7) 
2.6a 
(1.2-4.9) -0.11  
(-0.4-0.2) 
-0.20  
(-0.5-0.1) 
-0.23  
(-0.5-0.1) Change (%) at 3m  -0.1 (-3.3) -2.4 (-43.6) 
Change (%) at 6m  0.4 (13.3) -2.9 (-52.7) 
Note: Data was presented as median (interquartile range). Results were obtained from mixed method ANCOVA adjusted for baseline covariates; superscript “a” 
denotes significance compared to baseline; 3m, 3 months; 6m, 6 months. Significant at p<0.05. 
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Table 6. Adipocytokines and Endotoxin Before and After Intervention with Placebo or Probiotics among T2DM Patients. 
Parameter Placebo (N=30) Probiotics (N=31) Intervention Effects (CI 95%) 
Baseline 3 months 6 months Baseline 3 months 6 months 0-3 months 0-6 months Over-all 
Leptin (pg/ml) 
3.9 
(1.6-7.6) 
4.0 
(1.6-7.0) 
2.8 
(0.9-6.9) 
5.8 
(2.5-17.2) 
3.5 
(2.2-10.0) 
3.1 
(2.1-9.7) 0.24  
(-0.1-0.6) 
0.20  
(-0.2-0.6) 
0.22  
(-0.2-0.6) Change (%) at 3m  0.1 (2.6) -2.3 (-39.7) 
Change (%) at 6m  -1.1 (-28.2) -2.7 (-46.6) 
Adipo (µg/ml) 
11.1 
(8.7-16.6) 
9.7 
(5.1-16.8) 
11.1 
(5.7-16.0) 
8.5 
(6.4-14.6) 
10.4 
(7.2-18.7) 
14.6a 
(7.8-24.4) -0.08  
(-0.3-0.1) 
-0.04  
(-0.2-0.2) 
-0.02 
(-0.2-0.2) Change (%) at 3m  -1.4 (-12.6) 1.9 (22.4) 
Change (%) at 6m  0 (0) 6.1 (71.8) 
Resistin (ng/ml) 
6.3 
(4.2-11.4) 
11.8 
(6.2-19.1) 
11.3 
(5.3-15.2) 
11.7 
(6.4-18.8) 
6.2 
(3.7-14.5) 
4.9a 
(3.1-8.3) 0.05  
(-0.2-0.3) 
-0.02 
(-0.2-0.2) 
-0.08 
(-0.3-0.1) Change (%) at 3m  5.5 (87.3) -5.5 (-47.0) 
Change (%) at 6m  5.0 (79.4) -6.8 (-58.1) 
Endo (IU/ml) 
2.1 
(1.2-4.4) 
1.9 
(1.0-2.9) 
2.9b 
(1.9-7.0) 
4.6 
(2.4-7.9) 
2.2a 
(1.2-3.6) 
1.4a 
(1.0-2.1) 0.13  
(-0.1-0.4) 
-0.10 
(-0.4-0.1) 
-0.10 
(-0.3-0.1) Change (%) at 3m  -0.2 (-9.5) -2.4 (-52.2) 
Change (%) at 6m  0.8 (38.1) -3.2 (-69.6) 
Note: Data was presented as median (interquartile range). Results were obtained from mixed method ANCOVA adjusted for baseline covariates; superscript “a” 
denotes significance compared to baseline; superscript “b” denotes significance compared to 3 months; Adipo, adiponectin; Endo, endotoxin; 3m, 3 months; 6m, 
6 months. Significant at p<0.05. 
 
